1. Home
  2. RFI vs BNTC Comparison

RFI vs BNTC Comparison

Compare RFI & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Total Return Realty Fund Inc.

RFI

Cohen & Steers Total Return Realty Fund Inc.

SELL

Current Price

$10.43

Market Cap

293.3M

Sector

Finance

ML Signal

SELL

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

HOLD

Current Price

$8.16

Market Cap

313.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFI
BNTC
Founded
1992
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.3M
313.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RFI
BNTC
Price
$10.43
$8.16
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $24.33
AVG Volume (30 Days)
101.1K
★ 187.5K
Earning Date
01-01-0001
11-13-2026
Dividend Yield
★ 8.25%
N/A
EPS Growth
N/A
★ 6.67
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.25
$8.25
52 Week High
$12.07
$16.76

Technical Indicators

Market Signals
Indicator
RFI
BNTC
Relative Strength Index (RSI) 41.42 28.71
Support Level $10.25 N/A
Resistance Level $10.56 $14.09
Average True Range (ATR) 0.16 0.62
MACD 0.02 -0.02
Stochastic Oscillator 38.52 4.83

Price Performance

Historical Comparison
RFI
BNTC

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

Share on Social Networks: